HCV Policy & Advocacy
9. HIV and Hepatitis C Treatment Cost and Barriers to Access
- Details
- Category: HIV Policy & Advocacy
- Published on Wednesday, 30 December 2015 00:00
- Written by Liz Highleyman
Lack of access to HIV and hepatitis C treatment were key issues this year, as studies showed that type of health insurance affects the likelihood of successful treatment. HIV now has the potential to be a chronic manageable illness and hepatitis C can usually be cured, but major barriers and disparities continue to keep many people from accessing treatment.
Sofosbuvir/Daclatasvir Combination Could Be Produced for $200 per Hepatitis C Cure
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 15 December 2015 00:00
- Written by Keith Alcorn
Month-by-month tracking of the prices paid in India for the chemicals used to make direct-acting antivirals to treat hepatitis C shows that it is now possible to make and sell a combination of drugs to cure hepatitis C virus (HCV) infection for less than $200, Andrew Hill of Liverpool University said at the Second European HIV Hepatitis Co-infection Conference in London last week.
AASLD 2015: Liver Doctors and Advocates Call for Wider Treatment of People with Hepatitis C
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 17 November 2015 00:00
- Written by Liz Highleyman
AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
- Details
- Category: HCV Policy & Advocacy
- Published on Thursday, 19 November 2015 00:00
- Written by Keith Alcorn
Around 1 in 6 people with hepatitis C in 4 U.S. states had their prescriptions for direct-acting antivirals for hepatitis C refused by private insurers, and almost half of Medicaid recipients were denied reimbursement in 2014 and early 2015, according to findings presented this week at the 2015 AASLD Liver Meeting in San Francisco.
State Medicaid Programs Should Cover Hepatitis C Treatment, Federal Agency Says
- Details
- Category: HCV Policy & Advocacy
- Published on Tuesday, 10 November 2015 00:00
- Written by Liz Highleyman
The Centers for Medicare & Medicaid Services last week issued a letter to state Medicaid programs stating that they are expected to cover new interferon-free antiviral therapies for hepatitis C without undue restrictions, as well as a letter to the pharmaceutical companies that make these drugs asking about purchasing arrangements to ensure wider access.
Web Design and Development by